生物基因获得Vanqua Bio口服C5aR1 炎症抑制剂的专有权利,预付70M元,达到990M元的里程碑。 Biogen acquires exclusive rights to Vanqua Bio’s oral C5aR1 inhibitor for inflammatory diseases, paying $70M upfront and up to $990M in milestones.

根据2025年10月24日公布的一项协议, Vanqua Bio 的预先临床口服C5aR1对抗者(一种潜在的炎症治疗方法)获得了专属全球权利。 Biogen has acquired exclusive global rights to Vanqua Bio’s preclinical oral C5aR1 antagonist, a potential treatment for inflammatory diseases, under a deal announced October 24, 2025. 该化合物向关键免疫通路,参与中性粒细胞驱动的炎症,具有有前临床结果和支持临床发展的安全性. The compound targets a key immune pathway involved in neutrophil-driven inflammation, with promising preclinical results and a safety profile supporting clinical development. 生物基因计划将该方案推进到预期的2027年调查性新药物档案。 Biogen plans to advance the program toward an expected 2027 Investigational New Drug filing. 该公司将领导所有开发、制造和商业化活动,而Vanqua Bio则事先收到7 000万美元,达到9.9亿美元的里程碑和特许使用费。 The company will lead all development, manufacturing, and commercialization, while Vanqua Bio receives $70 million upfront, up to $990 million in milestones, and royalties. 在Biogen的2025年Q4结果中,预付付款将记为研发费用。 The upfront payment will be recorded as an R&D expense in Biogen’s Q4 2025 results. Vanqua将利用这些资金来推进其神经退化性疾病计划,特别是帕金森的研究。 Vanqua will use the funds to further its neurodegenerative disease programs, particularly Parkinson’s research. 该举措加强了生物基因的免疫管道,在多种免疫媒介条件下实行一流口服治疗。 The move strengthens Biogen’s immunology pipeline with a first-in-class oral therapy applicable to multiple immune-mediated conditions.